Veru (NASDAQ:VERU) Announces Earnings Results

Veru (NASDAQ:VERU) issued its quarterly earnings results on Thursday. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.

Veru Stock Up 3.0 %

Shares of Veru stock traded up $0.02 on Friday, hitting $0.54. The stock had a trading volume of 1,855,548 shares, compared to its average volume of 6,253,218. The stock’s 50-day simple moving average is $0.71 and its two-hundred day simple moving average is $0.77. Veru has a one year low of $0.40 and a one year high of $1.92. The stock has a market cap of $79.24 million, a price-to-earnings ratio of -1.93 and a beta of -0.54.

Analyst Upgrades and Downgrades

A number of research analysts have commented on VERU shares. Oppenheimer reiterated an “outperform” rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Veru in a report on Thursday, January 2nd.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.